Fundraising FoxSan Francisco · Seed–Series A · 1 people tracked
Find your way into BioRock Ventures
Sign up to see every warm intro you have to BioRock Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BioRock Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
BioRock Ventures focuses on seed-sized investments into private life science companies building best-in-class, FDA-regulated therapeutic drugs. The fund invests across all disease areas, all stages, and all therapeutic modalities, participating from angel and seed through Series A and up to pre-IPO or M&A exits.
Source: firm website, verified Aug 7, 2026.
Team · 1 people
from the firm's website
What they invest in
from 6 of 7 portfolio companiesBiotech ×6Healthtech ×5Deep Tech ×2Medical Devices ×2AI & Machine Learning ×1
HQs:United States×5
Investments · 7 tracked
founders shown can be your intro path
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.
BiotechHealthtechMenlo Park, US
Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Sanjay Chanda(Chief Development Officer)inLucy O. Day(Chief Financial Officer)in
Co-investorsAdjuvant CapitalFlucas VenturesMountain Group CapitalRA CapitalBiotechnology Value FundHatteras Venture Partners
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Grant Pickering(Founder)in
PartnerMary Wheeler· solo GP
Co-investorsCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesLongitude CapitalPivotal Life SciencesRA Capital+3 more
Gen1e builds healthcare solutions supported by a network of physicians across hospitals and medical centers.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Francisco, US
Ritu Lal(Founder)inSoujanya Bhumkar(Executive Officer, Director)Clint Webb
BoardNoor Kamruddin(Director)Francois Nader(Director)Alan Levy(Director)
Co-investorsClear VenturesY CombinatorKhosla VenturesEndurance28Flucas VenturesHarmonix Fund+13 more
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.
BiotechDeep TechHealthtechSeattle, US
Matthew Scholz(Founder)inSean Ainsworth(Chief Executive Officer)inRobert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)inScott McIvor(Chief Development Officer)Eric Garcia(Executive Officer)in
Co-investorsBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital NetworkNYBC Ventures+6 more
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy.
BiotechHealthtechCarlsbad, US
James Appleman(SVP, R&D and CSO, Cofounder)Paulo Rangel(Chief Business Officer and Cofounder)inStephen Webber(Vice President, Medicinal Chemistry, and Cofounder)inCharles McDermott(President & CEO, Director)
BoardTodd J Harris(Director)in
Co-investorsBioBritSamsara BioCapitalBioqube VenturesOberland CapitalPolaris Partners
PTM Therapeutics is a biotechnology company developing therapeutic candidates.
BiotechMedical DevicesBedford, US
Jennifer C. Cheng(CEO/Co-Founder)Tony W. Liang(VP of Research/Co-Founder)inCharles A. Parkos(Scientific Co-Founder)Jennifer C. Brazil(Scientific Co-Founder)
Co-investorsBioBrit
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AN2
Exits · 2
2 IPOsAN2 TherapeuticsNASDAQ: ANTXVaxcyteNASDAQ: PCVX
Portfolio news
latest coverage across their companiesVaxcyte · manilatimes.net · Aug 27, 2026
Immusoft · immusoft.com · Mar 30, 2026
Primmune Therapeutics · globenewswire.com · Jan 26, 2026
Frequently asked questions
- How many investments has BioRock Ventures made?
- BioRock Ventures has 7 tracked investments, 2 of which have exited, including 1 dated in the last 24 months.
- What stage does BioRock Ventures invest at?
- BioRock Ventures invests at the Seed, Series A stages.
- What sectors does BioRock Ventures focus on?
- BioRock Ventures focuses on Biotech, Healthtech, Medical Devices.
- Where is BioRock Ventures located?
- BioRock Ventures is headquartered in San Francisco, US.
- Who does BioRock Ventures co-invest with?
- BioRock Ventures most often shares deals with BioBrit, RA Capital, Breakout Ventures, among 19 tracked co-investors.
Media · Podcasts & interviews
featuring the teamMary Wheeler: General Partner of BioRock Ventures
Sutton Capital: THE INVESTOR with Joel Palathinkal · Mary Wheeler
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.